An analysis of how Meta and OpenAI are moving deeper into neurotechnology, from brain models to interface bets, and why governance, incentives, and questions of public trust now matter more to the field.

Synchron’s Kurt Haggstrom discusses BCI commercialization, reimbursement, competition, and why minimally invasive implants may matter more than headline-driven narratives.

Neurotechnology is starting to enter addiction care through withdrawal support, cue-reactivity assessment, and digital biomarkers. But most approaches remain early and difficult to scale.